Agios Pharmaceuticals, Inc.
Cambridge
Massachusetts
United States
345 articles about Agios Pharmaceuticals, Inc.
-
Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021
7/15/2021
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat genetically defined diseases, announced that the company will host a conference call and live webcast on Thursday, July 29, 2021 at 8:00 a.m. ET to report its second quarter 2021 financial results and other business highlights.
-
Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
6/28/2021
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, announced that it has submitted a Marketing Authorisation Application for mitapivat to the European Medicines Agency for the treatment of adults with pyruvate kinase deficiency in the European Union.
-
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
6/21/2021
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, announced that it has submitted a New Drug Application for mitapivat to the U.S. Food and Drug Administration for the treatment of adults with pyruvate kinase deficiency.
-
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress
6/11/2021
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat genetically defined diseases, announced positive results from its Phase 2, open-label, multicenter study of mitapivat in adults with non-transfusion dependent α- or β-thalassemia.
-
Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress
6/11/2021
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat genetically defined diseases, reported a full analysis of updated data, including patient-reported outcome measures, from its global Phase 3 ACTIVATE and ACTIVATE-T studies of mitapivat in adults with pyruvate kinase deficiency.
-
BioSpace looks at five of the top investor companies that support life sciences companies across the industry.
-
The Rare Disease Company Coalition’s 10 founding members have brought 22 treatments to market and currently have more than 160 rare disease programs in the works.
-
Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress
5/12/2021
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that mitapivat clinical data will be presented at the European Hematology Association (EHA) Annual Congress being held virtually June 9-17, 2021.
-
Agios Reports Business Highlights and First Quarter 2021 Financial Results
4/29/2021
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today reported business highlights and financial results for the first quarter ended March 31, 2021
-
Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021
4/15/2021
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that the company will host a conference call and live webcast on Thursday, April 29, 2021 at 8:00 a.m. ET to report its first quarter 2021 financial results and other business highlights.
-
Servier Completes Acquisition of Agios Pharmaceuticals' Oncology Business
4/1/2021
Transaction includes TIBSOVO®, co-commercialization responsibilities for Bristol Myers Squibb's IDHIFA® as well as a strong oncology pipeline of Phase 3 and early-stage assets
-
Agios Announces Closing of Oncology Business Sale to Servier
4/1/2021
Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio Agios Enters Into Agreement to Repurchase Approximately 10% of Its Outstanding Shares from Bristol-Myers Squibb for $344.5 Million
-
Agios Shareholders Approve Sale of Oncology Business to Servier
3/25/2021
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that its shareholders voted to approve the previously disclosed sale of its commercial, clinical and research-stage oncology portfolio to Servier Pharmaceuticals, LLC, an independent global pharmaceutical company.
-
Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease
3/18/2021
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, announced it will sponsor Citizen Scientist: Unpacking the Science of Sickle Cell Disease, an initiative developed by the Sickle Cell Community Consortium to promote health literacy for sickle cell patients.
-
Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias
2/26/2021
– In Partnership with the Sickle Cell Community Consortium, Agios Works to Address Educational Resource Gaps Caused by COVID-19 for Students with Sickle Cell Disease – – Company to Host Facebook Live Discussion with Pyruvate Kinase (PK) Deficiency Patient, Caregiver and Key Opinion Leader Today at 2 p.m. ET –
-
Agios Reports Fourth Quarter and Full Year 2020 Financial Results
2/25/2021
– Strong Commercial Execution for Second Full Year of TIBSOVO ® with Fourth Quarter Net Revenue of $39.1M and $121.1M for Full Year 2020 – – Sale of Oncology Portfolio Expected to Close Around March 31 Subject to March 25 Shareholder Vote, Allowing Agios to Focus on Genetically Defined Diseases – – Company Outlines Pivotal Development Program for Mitapivat in Sickle Cell Disease, Enabling a Potential Broad Label by Year-end 2026 –
-
Agios to Present at March Investor Conferences
2/23/2021
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the following March investor conferences: Cowen 41 st Annual Virtual Healthcare Conference on Monday, March 1, 2021 at 11:40 a.m. ET; and Oppenheimer 31 st Annual Virtual Healthcare Conference on Wednesday, March 17, 2021 at 9:20 a.m. ET.
-
Agilent is one of seven health care companies to make the fourth annual list of 100 companies compiled by the publication.
-
Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021
2/11/2021
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company will host a conference call and live webcast on Thursday, February 25, 2021 at 8:00 a.m
-
Clinical Catch-Up: January 25-29
2/1/2021
It was a busy week for clinical trial news. Read on for more information.